Outcomes of Percutaneous Coronary Intervention in Patients With Crohn's Disease and Ulcerative Colitis (from a

Ofer Kobo1, Mohamed O Mohamed2, Adam D Farmer3

  • 1Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Insights

Patients with inflammatory bowel disease (IBD) face lower risks for major adverse cardiovascular events after percutaneous coronary intervention (PCI). However, IBD patients experience a significantly higher risk of major bleeding post-PCI, necessitating further long-term safety evaluations.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Public Health

Background:

  • Inflammatory bowel disease (IBD) patients have a higher risk of ischemic heart disease.
  • Limited data exists on percutaneous coronary intervention (PCI) outcomes for IBD patients compared to those without IBD.

Purpose of the Study:

  • To compare in-hospital outcomes after PCI in patients with and without IBD.
  • To assess the association between IBD subtypes (Crohn's disease and ulcerative colitis) and PCI outcomes.

Main Methods:

  • Analysis of PCI-related hospitalizations from the National Inpatient Sample (2004-2015).
  • Stratification into no-IBD, Crohn's disease (CD), and ulcerative colitis (UC) groups.
  • Assessment of in-hospital outcomes including major adverse cardiovascular and cerebrovascular events, mortality, and major bleeding.

Main Results:

  • 0.3% of 6,689,292 PCI procedures involved patients with IBD; IBD prevalence increased from 2004 to 2015.
  • IBD patients were less likely to have traditional cardiovascular risk factors and more likely to undergo PCI for acute indications.
  • IBD patients showed reduced odds of major adverse cardiovascular/cerebrovascular events and mortality, but increased odds of major bleeding compared to no-IBD patients.

Conclusions:

  • IBD is associated with a decreased risk of in-hospital post-PCI complications, excluding major bleeding.
  • IBD patients undergoing PCI have a significantly higher risk of major bleeding.
  • Long-term follow-up is crucial to evaluate the overall safety of PCI in IBD patients, considering both bleeding and ischemic risks.

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
339
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
791
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
731
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
346
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
544
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
330